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INTRODUCTION
Methylmalonic aciduria due to mutations in MUT gene (MMA mut type, OMIM 251000) is a rare metabolic disorder, with autosomal recessive inheritance, resulting from
methylmalonyl CoA mutase (MCM, EC 5.4.99.2) apoenzyme deficiency.
MCM is a nuclear-encoded mitochondrial matrix homodimer, which uses adenosylcobalamin as an essential cofactor. Based on the complete or partial absence of
functional MCM, and in the response to adenosylcobalamine, two distinct biochemical phenotypes can be associated with MMA mut type: mut0 and mut- forms,
respectively (Fenton et al., 2001).
MUT gene is located on chromosome 6 and consists of 13 exons spanning over 35 kb of genomic DNA (Jansen et al., 1989). The 2.7 kb expressed mRNA encodes a 750
amino acids protein with a 32 residues mitochondrial targeting sequence. Each MCM monomer comprises different functional domains (Figure 1): a N-terminal extended
segment involved in dimerization, a N-terminal (βα)8 substrate binding domain and a C-terminal (βα)5 cobalamin binding domain, both linked through a long linker region
(Fuchshuber et al., 2000).
PATIENT AND METHODS
Since the inclusion of MMA mut type in the Portuguese Newborn Screening panel
in 2004 (Vilarinho et al., 2010), approximately 715,000 newborns have been
tested through tandem mass spectrometry analysis of acylcarnitines and amino
acids as butyl esters (Rashed et al., 1995). MMA patients were identified through
elevated C3 (propionylcarnitine) and C3/C2 ratio.
Suspected cases were confirmed through acylcarnitines analysis in a new blood
spot sample, organic acid analysis in urine and total homocysteine determination
in plasma.
Genomic DNA was extracted from dried blood spots in the BioRobot®EZ1, using
the EZ1 DNA Tissue Kit from Qiagen. MUT gene whole coding sequence and exon-
intron flanking regions were PCR amplified (Aquaviva, 2005) and directly
sequenced on an ABI3130XL DNA Anallyzer, using the BigDye Terminator Cycle
Sequencing Version 3.1 from Applied Biosystems.
RESULTS AND DISCUSSION
Three cases confirmed to have MMA mut type, which reveals a low frequency for
this disease in Portugal (1:238.333). In contrast to most other countries, MMA due
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Mut class*
p.R108C c.322C>T (βα)8 mut
0
p.N341Kfs*20 c.1022dupA (βα)8 mut
0
p.G626Efs*18 c.1877-1889del13 (βα)5 mut
0
p.G717V c.2150G>T (βα)5 mut
-
Gene bank reference sequence NM_000255.2. *More frequently associated 
mut class. 
Table 2 – Mutations identified in MMA mut type newborns
p.G717V is typically a mut- mutation, frequent among Africa originating people
(Adjalla et al., 1998; Worgan et al., 2006). The severity of the clinical phenotype
and the fact that at least one mut0 case was reported which was a compound
heterozigote for p.G717V and a mut0 mutation (Worgan et al., 2006), may suggest
that this can also be a mut0 patient. Nevertheless, although it seems to exist a
to cobalamin C/D deficiency (1:80.000) is much more frequent. All three patients
presented a severe clinical phenotype, with clinical symptoms already visible at
the sampling day.
Four different mutations were identified (Table 1), all localizing in the 2 main MCM
functional domains (Table 2, Figure 1), as reported for most mutations.
Patient Sex NBS day NBS  results Genotype
1 M 2
C3=13.1 µM (N<6.2)
C3/C2=0.51 (N< 0.3)
p.G626Efs*18 / 
p.G626Efs*18
2 M 3
C3=12.4 µM (N<6.2)
C3/C2=0.84 (N< 0.3)
p.G717V / p.R108C
3 M 5
C3=7.0 µM (N<6.2)
C3/C2=0.70 (N<0.3)
p.N341Kfs*20 / 
p.G626Efs*18
Table 1 – MMA, mut type newborn screening patients 
correlation between the genotype and the biochemical phenotype, this
correlation is not straightforward regarding the clinical phenotype and mut-
patients can also exhibit severe clinical symptoms. This was reported for patients
homozygous for mutation p.G717V (Worgan et al., 2006) and can also be the case
for this patient.
Figure 1 - Functional domains of MUT gene and localization of mutations found in 
Portuguese newborn screening patients
G717VR108C p.G626Efs*18p.N341Kfs*20
21 3 4 5 6 7 8 9 10 11 12 13
(βα)5 cobalamin-
binding domain
Linker domain
(βα)8 substrate-
binding domain
Dimerization
domain
Mitochondrial
targeting
sequence
Patient 1 is homozygous for a frameshift mutation previously reported in one
mut0 European patient (Aquaviva et al., 2005). Attending to the severity of the
clinical symptoms, our case is probably also a mut0 patient, although most
mutations locating in the cobalamin binding domain are reported to be mut-
mutations.
This mutation was also found in patient 3, despite the fact that their families don’t
seem to be related. Mutation c.1022dupA, also present in patient 3, is a frameshift
mutation relatively frequent among Hispanic and Spanish patients (Martinez et al.,
2005; Worgan et al., 2006) and reported to be associated to the mut0 phenotype.
This patient is probably also a mut0 patient.
Patient 2 is a compound heterozygote for two missense mutations. Mutation
p.R108C, locates in the substrate-binding domain and is also a mut0 mutation,
frequent among Hispanic and Spanish patients.
CONCLUSIONS
•MMA mut type is very rare in Portugal (approximate frequency < 1:200.000), but
clinical severe forms seems to dominate, thus stressing the importance of early
identification through newborn screening.
•Three newborn screening identified patients were studied at the molecular level
and four different mutations were found: two of them are frequent among Spanish
and Hispanic and another one, found in a Portuguese family with probable African
origin, is frequent among black people. The fourth mutation is rare worldwide, but
it was found in two non-related families, which may suggest some importance in
the genetic epidemiology of the disease in Portugal.
•The molecular characterization of these patients contributed to the elucidation of
the genetic epidemiology of the disease in Portugal, and is essential for genetic
counseling and early prenatal diagnosis in at-risk families. The fact that novel
antisense and antigenic therapies, based on the genotype, are being proposed for
MCM deficiency also increases the importance of genotype determination.
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